LONDON and SALT LAKE CITY, Feb. 15, 2024 Renalytix plc , an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today.
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled.
LONDON and SALT LAKE CITY, Feb. 09, 2024 Renalytix plc today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools.
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months .